Effect of Brazilian Propolis on Exacerbation of Respiratory Syncytial Virus Infection in Mice Exposed to Tetrabromobisphenol A, a Brominated Flame Retardant
Overview
Authors
Affiliations
Tetrabromobisphenol A (TBBPA), a brominated flame retardant, has been found to exacerbate pneumonia in respiratory syncytial virus- (RSV-) infected mice. We examined the effect of Brazilian propolis (AF-08) on the exacerbation of RSV infection by TBBPA exposure in mice. Mice were fed a powdered diet mixed with 1% TBBPA alone, 0.02% AF-08 alone, or 1% TBBPA and 0.02% AF-08 for four weeks and then intranasally infected with RSV. TBBPA exposure increased the pulmonary virus titer and level of IFN- γ , a representative marker of pneumonia due to RSV infection, in the lungs of infected mice without toxicity. AF-08 was significantly effective in reducing the virus titers and IFN- γ level increased by TBBPA exposure. Also, AF-08 significantly reduced proinflammatory cytokine (TNF- α and IL-6) levels in the lungs of RSV-infected mice with TBBPA exposure, but Th2 cytokine (IL-4 and IL-10) levels were not evidently increased. Neither TBBPA exposure nor AF-08 treatment affected the anti-RSV antibody production in RSV-infected mice. In flow cytometry analysis, AF-08 seemed to be effective in reducing the ratio of pulmonary CD8a(+) cells in RSV-infected mice with TBBPA exposure. TBBPA and AF-08 did not exhibit anti-RSV activity in vitro. Thus, AF-08 probably ameliorated pneumonia exacerbated by TBBPA exposure in RSV-infected mice by limiting excess cellular immune responses.
Update of the scientific opinion on tetrabromobisphenol A (TBBPA) and its derivatives in food.
Schrenk D, Bignami M, Bodin L, Chipman J, Del Mazo J, Grasl-Kraupp B EFSA J. 2024; 22(7):e8859.
PMID: 39010865 PMC: 11247339. DOI: 10.2903/j.efsa.2024.8859.
Ferrucci V, Miceli M, Pagliuca C, Bianco O, Castaldo L, Izzo L J Transl Med. 2024; 22(1):574.
PMID: 38886736 PMC: 11184722. DOI: 10.1186/s12967-024-05378-2.
Hive Products: Composition, Pharmacological Properties, and Therapeutic Applications.
Bava R, Castagna F, Lupia C, Poerio G, Liguori G, Lombardi R Pharmaceuticals (Basel). 2024; 17(5).
PMID: 38794216 PMC: 11124102. DOI: 10.3390/ph17050646.
Magnavacca A, Sangiovanni E, Racagni G, DellAgli M Med Res Rev. 2021; 42(2):897-945.
PMID: 34725836 PMC: 9298305. DOI: 10.1002/med.21866.
Nainu F, Masyita A, Bahar M, Raihan M, Prova S, Mitra S Antibiotics (Basel). 2021; 10(7).
PMID: 34356743 PMC: 8300842. DOI: 10.3390/antibiotics10070822.